About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

BAX 326 Surgery Study in Hemophilia B Patients | Clinical Trials | Clareo Health

COMPLETEDPhase 3

BAX 326 Surgery Study in Hemophilia B Patients

BAX 326 (Recombinant Factor IX): A Phase 3 Prospective, Multicenter Study Evaluating Efficacy and Safety in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B Undergoing Surgical or Other Invasive Procedures

NCT01507896•Baxalta now part of Shire

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Hemophilia B

Interventions

Recombinant factor IX

Locations

14

Argentina

Locations (14)

Instituto de Hematología y Medicina Clínica Rubén Dávoli

Rosario, Argentina

Specialized Haematological Hospital "Joan Pavel"

Sofia, Bulgaria

Hospital Dr. Sotero del Rio

Santiago, Chile

Centro Medico Imbanaco

Cali, Colombia

Klinika detska hematologie a onkologie, Fakultni Nemocnice Motol

Prague, Czechia

Medical University Lodz, Copernicus Hospital, Department of Hematology

Lodz, Poland

Key Dates

Start Date

December 19, 2011

Primary Completion Date

May 15, 2014

Completion Date

May 15, 2014

Last Updated

May 19, 2021

Related Studies

RECRUITINGPhase 1/2

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

NCT06008938

National Longitudinal Cohort of Hematological Diseases

NCT04645199

Multiple MyelomaAcute Myeloid Leukemia+15 more

RECRUITINGPhase 3

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

NCT07080905

RECRUITINGPhase 3

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

NCT06700096

Active Not RecruitingPhase 3

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

NCT06312475

Hemophilia A With InhibitorHemophilia B With Inhibitor

View all related studies

Sponsors

Lead Sponsor

Baxalta now part of Shire

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 19, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions